Conventional endocytosis-mediated delivery is limited by poor endosomal escape efficiency, making intracellular delivery of therapeutic biomacromolecules a long-standing challenge in modern biomedical research. The low endosomal escape efficiency of traditional endocytosis-dependent pathways remains a fundamental bottleneck restricting the clinical translation of therapeutic biomacromolecules. A review published in Biomedical Analysis focuses on emerging non-endocytic transmembrane delivery strategies, which bypass canonical cellular uptake routes to achieve direct cytosolic delivery of mRNA, proteins, nucleic acids, and gene-editing tools. Led by Dr. Yang Liu from the Institute of Energy, Hefei Comprehensive National Science Center , the review systematically outlines research progress in physical, bioengineered, and biomimetic delivery platforms, and discusses their application prospects in gene therapy, macromolecular drug delivery, and cellular engineering.
The review summarizes recent advances in several emerging non-endocytic delivery platforms, arranged in chronological order of development: physical temporary membrane permeabilization methods, cell-penetrating peptides, membrane fusion systems, virus-like particles, phase-separated carriers, and engineered biological nanomachines.
Physical approaches, such as electroporation, sonoporation, photothermal methods, and mechanical membrane modulation, create reversible transient pores in cell membranes to facilitate molecular transport. Advances in micro- and nanoscale engineering are helping improve delivery efficiency while minimizing cellular damage.
Biomimetic strategies, spanning peptide-based carriers to virus-inspired delivery systems, draw inspiration from natural biological processes to achieve more efficient intracellular transport. As the earliest bioengineered non-endocytic modality, cell-penetrating peptides laid the foundation for subsequent biomimetic designs. Membrane fusion systems and virus-like particles further evolved by leveraging natural membrane interaction mechanisms. Phase-separated carriers, emerging in recent years, have expanded the biomimetic toolbox with unique phase transition properties. Meanwhile, engineered biological nanomachines represent a particularly innovative direction by mimicking natural molecular delivery mechanisms to introduce functional biomolecules into cells.
Efficient intracellular delivery is a critical requirement for many emerging biomedical applications. For gene-editing technologies such as CRISPR systems, therapeutic molecules must reach specific intracellular locations to perform their functions. Similarly, mRNA therapeutics, protein-based therapies and cellular engineering approaches depend on reliable methods to transport functional biomolecules across cellular membranes.
The authors highlight that non-endocytic delivery strategies could become valuable tools for advancing next-generation therapies. However, several challenges remain, including improving delivery specificity, reducing potential immune responses, achieving scalable clinical-grade manufacturing, and ensuring long-term safety.
The review provides a comprehensive perspective on how researchers are moving beyond traditional delivery limitations toward more direct and efficient intracellular transport strategies. By overcoming the cellular membrane barrier, these emerging technologies may help expand the possibilities of biomacromolecule-based therapies and accelerate the development of future precision medicine approaches.
“Delivering functional biomacromolecules into cells remains a major bottleneck for many emerging biomedical therapies, largely due to the low endosomal escape efficiency of conventional endocytosis-dependent pathways. This review highlights how non-endocytic delivery strategies bypass canonical cellular uptake pathways and membrane barriers and provide new opportunities for gene therapy, mRNA therapeutics, protein therapeutics, and cellular engineering,” said Dr. Yang Liu, corresponding author of the review.
DOI: 10.1016/j.bioana.2026.05.003
Read the full article: https://doi.org/10.1016/j.bioana.2026.05.003
Biomedical Analysis invites submissions for its 2026 Special Issue, “Biosensing and Nanoanalytical Technologies,” scheduled for publication in December 2026. The issue welcomes original research articles and reviews on innovative biosensing strategies, nanoanalytical technologies, functional nanomaterials, optical and electrochemical sensing, signal amplification, imaging, microfluidic and point-of-care platforms, and biomedical applications in disease diagnosis and precision medicine.
The submission deadline is September 30, 2026 . Please refer to the Guide for Authors to prepare your manuscript and select the article type of ": “VSI: Biosensing and Nanoanalytical Technologies" when submitting your manuscript online. Submit your manuscript at: https://www2.cloud.editorialmanager.com/bioana/default2.aspx
Biomedical Analysis is an international, peer-reviewed, open access journal published by Elsevier and KeAi and jointly sponsored by Sun Yat-sen University and the Guangzhou Analysis and Testing Center.
The journal publishes high-quality research in biomedical engineering, bioanalytical chemistry, biochemistry, genetics, biology, biomaterials, medicine, and related interdisciplinary fields, with a particular focus on biomedical testing, sensing technologies, and analytical innovation. Biomedical Analysis is indexed in Scopus, CAS, DOAJ, and EBSCO. Article processing charges (APCs) are currently waived for accepted manuscripts through the end of 2026.
Journal website: https://www.sciencedirect.com/journal/biomedical-analysis .
Biomedical Analysis
Literature review
Cells
Progress in non-endocytic dependent transmembrane delivery of biological macromolecules
20-Jun-2026
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.